Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Degludec insulin · Insulin Degludec, Tresiba

Recombinant protein · Agonist of insulin receptor (INSR) · developed by Novo Nordisk

Approved FDA, Sep 2015
1 Registered trials

What is Degludec insulin?

Insulin degludec is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. It is used to improve glycemic control in diabetes mellitus. It is also combined with liraglutide, a GLP-1 receptor agonist, in one product.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Insulin Degludec, Tresiba, Xultophy 100/3.6
Drug type
Recombinant protein
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Pathways
glucose uptake, hepatic glucose production inhibition, lipolysis inhibition, protein synthesis
Therapy area
Endocrine
Developer
Novo Nordisk
In trials of
SBFM
FDA status
Approved as Insulin Degludec, Tresiba, Xultophy 100/3.6 (September 25, 2015), BLA208583 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 22, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07376200 Phase 1 Healthy Adult Male Recruiting SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Adult Male

Other drugs acting on INSR

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.